உயிர் அறிவியல் சிறுநீரகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
-
AI-generated target was identified through The Benevolent Platform and AstraZeneca s scientific expertise and rich datasets
LONDON, Jan. 27, 2021 /PRNewswire/ BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company s portfolio. The Benevolent Platform predicted this novel target, which was subsequently biologically validated through AstraZeneca s rigorous experimental testing.
In 2019, BenevolentAI and AstraZeneca entered a strategic collaboration aiming to discover new drugs for CKD and idiopathic pulmonary fibrosis (IPF). The partnership combines AstraZeneca s scientific expertise and rich datasets with BenevolentAI s target identification pl ....

New York , United States , City Of , United Kingdom , Prnewswire Benevolent , Rajin Kang , Anne Phelan , Pernille Laerkegaard Hansen , Benevolent Platform , Senior Director , Biosciences Renal , Chief Scientific Officer , Ulcerative Colitis , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , அன்னே ஃபெலன் , கருணைமிக்கவர் நடைமேடை , மூத்தவர் இயக்குனர் , உயிர் அறிவியல் சிறுநீரகம் , தலைமை அறிவியல் அதிகாரி ,